Journal of Oncology Pharmacy Practice最新文献_第5页

Conception of a board game as a training tool on the best practices for chemotherapy drug preparation. 构思一个棋盘游戏，作为化疗药物配制最佳做法的培训工具。

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2025-04-04 DOI: 10.1177/10781552251330270

Nawres Makhlouf, Zribi Kaouther, Amani Cherif, Olfa Gloulou, Emna Zribi

{"title":"Conception of a board game as a training tool on the best practices for chemotherapy drug preparation.","authors":"Nawres Makhlouf, Zribi Kaouther, Amani Cherif, Olfa Gloulou, Emna Zribi","doi":"10.1177/10781552251330270","DOIUrl":"10.1177/10781552251330270","url":null,"abstract":"ObjectivesThe aim of this study was to develop a gamified tool on best practices for chemotherapy drug preparation and validate it.MethodsThe conception process of the gamified instrument encompassed multiple integral steps to develop the tool and to assess its usability. To validate the tool, the game was tested by interns and residents at a Pharmacy Faculty over a single day, a pre-test and post-test assessments were conducted with participants before and after playing the game to evaluate the utility of the gamified tool. The exploitation of the results was carried out using a student's t-test statistical analysis. Then, participant satisfaction was evaluated through a questionnaire and results was analysed using Excel®.ResultsThe gamified tool (ChemINJ) is a board game designed for two to four players. The game board have 59 squares of different colours, corresponding to a theme of the questions cards. The questions are divided into three themes: protection, preparation, and administration, with a total of 244 questions. The game was applied with the participation of 24 participants across six tournaments. Eighteen out of 24 expressed a high level of satisfaction regarding the knowledge achieved through ChemINJ, and 23 players expressed their desire to play ChemINJ again. The game is considered as a continuous training tool inspired by the game of the goose® and Trivial Pursuit®.ConclusionChemINJ offers a gamification approach to enhance knowledge in the field of manipulation of anticancer drugs. Therefore, it is suggested to integrate it into the curriculum for students.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1191-1199"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Real-world evaluation of therapeutic anticoagulation for cancer-associated thromboembolism: A retrospective analysis. 治疗抗凝治疗癌症相关血栓栓塞的真实世界评价：回顾性分析。

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2025-04-01 DOI: 10.1177/10781552251331559

Juri Chung, Joshua Park, Jamie Chin-Hon, Meredith Akerman, Alexander Hindenburg

{"title":"Real-world evaluation of therapeutic anticoagulation for cancer-associated thromboembolism: A retrospective analysis.","authors":"Juri Chung, Joshua Park, Jamie Chin-Hon, Meredith Akerman, Alexander Hindenburg","doi":"10.1177/10781552251331559","DOIUrl":"10.1177/10781552251331559","url":null,"abstract":"BackgroundThrombosis is the second leading cause of death in cancer patients and treatment for thrombosis and prevention for secondary prophylaxis is anticoagulation. Low-molecular-weight heparin (LMWH) is more effective than vitamin K antagonists for the treatment of cancer-associated thromboembolism (CAT). Direct oral anticoagulants (DOACs) are non-inferior to dalteparin in treating CAT with similar major bleeding risks. Major guidelines recommend DOACs for CAT; however, data comparing individual DOACs to enoxaparin is lacking. The purpose of this study is to evaluate the efficacy and safety of DOACs compared to LMWH for CAT.MethodsA multi-site retrospective review was conducted in adult cancer patients with a CAT history who received either a DOAC (apixaban or rivaroxaban) or LMWH (enoxaparin). Primary efficacy and safety endpoints were recurrent thromboembolism and major bleeding occurrences. Secondary endpoints included time to subsequent CAT occurrence, time to first bleed event post initial CAT, and incidence of clinically relevant non-major and minor bleeding.ResultsA total of 102 patients were included in the study. There was no significant difference among the groups with respect to time to subsequent CAT (p = 0.5625). However, patients who received apixaban and rivaroxaban had a 2.39 times and 3.26 times higher risk of subsequent CAT respectively compared to those who received enoxaparin. Major bleeding rates were also not statistically significant (p = 0.465), despite enoxaparin having the highest rate at 8.8% and no rivaroxaban patients experiencing major bleeding.ConclusionNo differences were observed between rivaroxaban, apixaban, and enoxaparin in rates of recurrent venous thromboembolism (VTE) and bleeding.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1200-1206"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143764213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the effect of closed system transfer device syringe adaptor connection in the isolator on cytotoxic residue contamination during intravenous administration. 隔离器内封闭系统传递装置注射器接头连接对静脉给药过程中细胞毒残留污染的影响评价。

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2025-04-23 DOI: 10.1177/10781552251334027

Louisa Knowles

{"title":"Evaluation of the effect of closed system transfer device syringe adaptor connection in the isolator on cytotoxic residue contamination during intravenous administration.","authors":"Louisa Knowles","doi":"10.1177/10781552251334027","DOIUrl":"10.1177/10781552251334027","url":null,"abstract":"IntroductionThe European Biosafety Network recommends that cytotoxic drug surface contamination in pharmacies and patient wards not exceed 0.1 ng/cm2. Among other mitigations, closed system transfer devices (CSTDs) are recommended in the US, Europe, and UK for the reduction of surface contamination. Although in the UK CSTDs are not part of standard cytotoxic preparation procedures in isolators, CSTD syringe adaptors are recommended for use with syringes for intravenous administration. We investigated whether the addition of a CSTD syringe adaptor in the isolator reduces cytotoxic residue contamination during intravenous bolus administration.MethodsTwenty-five cyclophosphamide syringes were prepared with hub caps and twenty-five with SIMPLIVIA® (formerly Tevadaptor/OnGuard®) Syringe Adaptor Locks (SALs) in an isolator. Surface contamination of syringes, gauze pads placed at the administration site, and nurses' gloves was compared between the practice of connecting hub caps in the isolator and removing them in the ward versus connecting SALs in the isolator during preparation. Cyclophosphamide contamination was quantified by liquid-chromatography mass spectrometry.ResultsUse of SALs compared to standard hub caps led to statistically significant reduction in cyclophosphamide contamination on the syringes (2.41 ± 0.89 ng versus 33.42 ± 8.48 ng, p = 0.0007), the swabs used for connect/disconnect (0.01372 ± 0.01 ng versus 655.80 ± 190.18 ng, p = 0.001), and nurses' gloves (0.0009 ± 0.0009 ng versus 8.31 ± 3.94 ng, p = 0.04). When hub caps were used, 48% of syringes, 76% of gauze pads, and 8% of gloves exceeded the recommended limit of 0.1 ng/cm2, while no samples exceeded this limit with SAL.ConclusionsThe implementation of CSTD syringe adaptors was beneficial for reducing cytotoxic drug exposure to nurses administering intravenous syringes.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1266-1273"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578644/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of bevacizumab preparation conditions on inline-filter blockage. 贝伐单抗制备条件对内联过滤器堵塞的影响。

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2025-04-24 DOI: 10.1177/10781552251336176

Chiaki Ogawa, Megumi Yatabe, Yoshiyuki Nagayama, Kazuhiko Nakadate, Shigeru Adachi, Motoki Inoue

{"title":"Impact of bevacizumab preparation conditions on inline-filter blockage.","authors":"Chiaki Ogawa, Megumi Yatabe, Yoshiyuki Nagayama, Kazuhiko Nakadate, Shigeru Adachi, Motoki Inoue","doi":"10.1177/10781552251336176","DOIUrl":"10.1177/10781552251336176","url":null,"abstract":"PurposeThis study aimed to investigate the effects of preparation conditions and external factors, particularly ultraviolet (UV) exposure, on inline-filter clogging in liquid monoclonal antibody (l-mAb) formulations. Bevacizumab (BmAb) was used as a model drug to address the critical question of how UV exposure impacts protein stability and filter performance during clinical administration.MethodsBevacizumab solutions were exposed to UV-C (254 nm) light to evaluate its effects on protein stability and filter clogging. Scanning electron microscopy (SEM) was used to visualize protein aggregates on the filter surface. Dynamic light scattering (DLS) analysis measured particle size distribution and average particle size. To assess the effectiveness of light shielding, additional samples were prepared under conditions that minimized UV exposure.ResultsUV-C exposure induced significant precipitate formation, with SEM images revealing protein aggregates on the filter surface. DLS analysis showed a broader particle size distribution and an increase in average particle size (18.1 nm) in UV-exposed solutions compared to non-exposed controls. Light shielding effectively suppresses precipitate formation, maintaining the stability of BmAb solutions and preventing inline-filter clogging.ConclusionUV-C destabilizes BmAb solutions, leading to protein aggregation and inline-filter clogging. Light shielding was identified as an effective strategy to maintain the stability and safety of l-mAb formulations, particularly in settings where prolonged exposure to environmental light is possible. These findings emphasize the importance of implementing protective measures against UV exposure and call for further research on additional environmental factors and optimized protocols to enhance l-mAb formulation reliability.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1289-1294"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144022914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Bridging the pain gaps: Opioid access for cancer pain in rural Nepal and the untapped role of pharmacists. 弥合疼痛差距：阿片类药物获得癌症疼痛在尼泊尔农村和药剂师未开发的作用。

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2026-06-29 DOI: 10.1177/10781552261459922

Sunil Shrestha, Rajeev Shrestha, Sundus Shukar, Nabin Pathak

引用次数: 0

Author response. 作者的回应。

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2026-06-11 DOI: 10.1177/10781552261458251

Miguel Escario

引用次数: 0

Analysis of pembrolizumab in microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) non-colorectal patients with metastatic cancer. 派姆单抗在微卫星不稳定性高（MSI-H）和错配修复缺陷（dMMR）非结直肠癌转移癌患者中的应用分析

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2025-04-04 DOI: 10.1177/10781552251331958

Alexis Tandyk, Trevor Christ

{"title":"Analysis of pembrolizumab in microsatellite instability high (MSI-H) and deficient mismatch repair (dMMR) non-colorectal patients with metastatic cancer.","authors":"Alexis Tandyk, Trevor Christ","doi":"10.1177/10781552251331958","DOIUrl":"10.1177/10781552251331958","url":null,"abstract":"Pembrolizumab was approved for the treatment of MSI-H/dMMR solid malignancies in a tumor agnostic approval in 2017. Treatment records for patients harboring MSI-H/dMMR status at our institution treated with pembrolizumab were reviewed for outcomes of duration of treatment, progression free survival, and overall survival. Adverse events and immunotherapy biomarkers of PDL-1 status and tumor mutation burden (TMB) were also assessed. Thirty patients were included: 13 with endometrial cancer, 5 non-colorectal gastrointestinal cancer, 2 ovarian or uterine cancer, 2 breast cancer, and 8 with other malignancies. The median duration of treatment was 11 months (range 0-35). Progression free survival and overall survival were not reached. Five patients (16.7%) experienced immune related adverse events, resulting in discontinuation of pembrolizumab in 3. PDL-1 expression and TMB did not appear to correspond to treatment outcomes. This analysis provides a real-world dataset of MSI-H/dMMR solid tumor patients being treated with pembrolizumab, outcomes of which are consistent with registry trials.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1229-1234"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143780328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rethinking centralised oncology pharmacy practice in the era of flat-dose immunotherapy, subcutaneous formulations and visit-administration day separation: A conceptual analysis and reform proposal. 在平剂量免疫治疗、皮下制剂和访药日分离时代对集中肿瘤药学实践的反思：概念分析和改革建议。

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2026-04-13 DOI: 10.1177/10781552261443223

Mauro Iannopollo

{"title":"Rethinking centralised oncology pharmacy practice in the era of flat-dose immunotherapy, subcutaneous formulations and visit-administration day separation: A conceptual analysis and reform proposal.","authors":"Mauro Iannopollo","doi":"10.1177/10781552261443223","DOIUrl":"10.1177/10781552261443223","url":null,"abstract":"ObjectiveTo examine whether the centralised Oncology Pharmacy Unit (OPU) model, established in the late 1990s for BSA-dependent cytotoxic compounding, remains fit for purpose in a contemporary oncology context dominated by flat-dose immunotherapy and subcutaneous checkpoint inhibitor formulations, and to propose a stratified hybrid model proportional to actual preparation complexity.Data SourcesPublished clinical trial data for subcutaneous checkpoint inhibitors (IMscin001, CheckMate-67 T, IMscin002); EMA and FDA regulatory documents (2024-2025); peer-reviewed literature on flat-dose immunotherapy, time toxicity and oncology pharmacy workflow; institutional reports from IOV IRCCS Padua, NHS England, French SFPO and the Veneto Region Pharmacy Working Group.Data SummaryFour structural inefficiencies are documented: (1) identical compounding workflows applied to pharmacologically non-equivalent preparations; (2) subcutaneous formulations with up to 80% administration time reduction routed through the full compounding circuit without clinical justification; (3) per-preparation process costs exceeding vial-sharing savings for off-patent generics; and (4) same-day compression of clinical assessment, prescribing, compounding and administration generating structural day-hospital congestion and measurable patient time toxicity. A four-level stratified hybrid model is proposed: robotic automation for high-complexity cytotoxics, simplified workflow for flat-dose IV immunotherapy, ward-based preparation for subcutaneous products, and D/D + 1 visit-to-administration day separation as an institutional standard.ConclusionThe 1999 OPU model has outlived its pharmacological context. A stratified approach to oncology pharmacy organisation - proportional to actual preparation complexity - is operationally feasible, clinically safe and necessary to restore pharmacy resources to where they generate genuine value.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1391-1397"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147674306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis. 核糖环尼在接受慢性血液透析的HR+/HER2转移性乳腺癌患者中的安全应用

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2026-02-19 DOI: 10.1177/10781552261423942

Dilek Çağlayan, Melek Çağlayan

{"title":"Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis.","authors":"Dilek Çağlayan, Melek Çağlayan","doi":"10.1177/10781552261423942","DOIUrl":"10.1177/10781552261423942","url":null,"abstract":"İntroductionThe standard treatment for hormone receptor-positive and HER2-negative metastatic breast cancer is a combination of CDK4/6 inhibitors and endocrine therapy.Case reportIn this case, our aim was to demonstrate the safety and effectiveness of ribociclib in a patient with metastatic breast cancer undergoing hemodialysis three days a week.Management & OutcomeA 59-year-old female patient with end-stage kidney disease who undergoes hemodialysis was diagnosed with metastatic breast cancer. The tumour is hormone receptor positive and HER2 negative. She received ribociclib with a reduced dose due to haematological toxicity, as well as letrozole and denosumab due to bone metastasis. PET/CT scans revealed that the primary tumour had regressed by 50%, with partial regression of the metabolic activity of the bone metastases. Ribociclib was administered safely and effectively for nine months.DiscussionWe presented our experience of using ribociclib in a patient with metastatic breast cancer who was receiving hemodialysis. Ribociclib was administered safely, and a response to the treatment was achieved.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1398-1400"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13578641/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Comparison of carboplatin doses according to several formulae in a cohort of patients treated for an ovarian cancer in real life. 比较卡铂剂量根据几个公式在队列治疗卵巢癌在现实生活中。

IF 1.3 4区医学

Journal of Oncology Pharmacy Practice Pub Date : 2026-10-01 Epub Date: 2025-04-16 DOI: 10.1177/10781552251332600

Ali Hassan, Aurore Carrot, Reine Kimbidima, Olivier Colomban, Chloé Herledan, Olivier Glehen, Benoît You, Catherine Rioufol, Florence Ranchon

{"title":"Comparison of carboplatin doses according to several formulae in a cohort of patients treated for an ovarian cancer in real life.","authors":"Ali Hassan, Aurore Carrot, Reine Kimbidima, Olivier Colomban, Chloé Herledan, Olivier Glehen, Benoît You, Catherine Rioufol, Florence Ranchon","doi":"10.1177/10781552251332600","DOIUrl":"10.1177/10781552251332600","url":null,"abstract":"IntroductionCarboplatin doses are calculated using several formulae, with the most recent being the Calvert formula with Glomerular Filtration Rate estimated using the CKD Epi cystatin C (Calvert CKD-Epi Cys) equation. The aim of this study was to compare the carboplatin doses estimated by this formula with the most commonly used formulas.Materials and methodsThe carboplatin doses prescribed for 84 patients with ovarian cancer were calculated according to Chatelut, Calvert with Glomerular Filtration Rate estimated using Cockcroft and Gault (Calvert CG), CKD-Epi (Calvert CKD-Epi) equation, modified Thomas and Calvert CKD-Epi Cys formulas. First, these 4 formulas were compared with the Calvert CKD-Epi Cys formula using a Wilcoxon test for pairwise comparison, and by assessing mean predictive error (MPE), mean absolute percentage error (MAPE), and absolute percentage error over 20% (P20). A subgroup analysis was then performed to determine the clinical and biological parameters responsible for the observed differences.ResultsThomas modified formulas showed low bias (MPE = 1.5%) and good precision (MAPE = 4.5%). Chatelut and Calvert CG were less precise with P20 values of32.1% and 13.5% respectively. Differences were mostly due to body weight, age and plasma cystatin C levels. The Calvert CKD-Epi formula showed good precision (MAPE = 8.1%) and low bias (MPE = 2.4%) except when plasma cystatin C levels were equal or above normal range (MPE = 14.9%).ConclusionAs proposed by White-Koning et al., we have chosen Calvert CKD-Epi Cys formula as a reference for carboplatin dosage calculations in our hospital. However, the limited doses differences with the Calvert CKD-Epi formula make it another reliable option in clinical practice.","PeriodicalId":16637,"journal":{"name":"Journal of Oncology Pharmacy Practice","volume":" ","pages":"1241-1248"},"PeriodicalIF":1.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0